Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Lethal recessive chondrodysplasia is an extremely rare lethal form of chondrodysplasia characterized by severe micromelic dwarfism, short and incurved limbs with normal hands and feet, facial dysmorphism (disproportionately large skull, frontal prominence, slightly flattened nasal bridge and short neck), muscular hypotonia, hyperlaxity of the extremities, and a narrow thorax. Most patients die of respiratory distress during the first hours or weeks of life. There have been no further descriptions in the literature since 1988.
Features include always present findings: Narrow chest, Short long bone, Flared elbow metaphyses, and Accelerated skeletal maturation and others; and very common findings: Micrognathia and Polyhydramnios. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 3 | Short long bone, Accelerated skeletal maturation, Generalized osteosclerosis |
Biomarker and diagnostic research for lethal recessive chondrodysplasia has been reported in the published literature.
Phenotype severity distribution: 6 always present features, 2 very common features, 4 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for lethal recessive chondrodysplasia.
141 publications have been identified in PubMed for lethal recessive chondrodysplasia. Research spans Review / Meta-Analysis (67%), Basic Science / Preclinical (13%), and Epidemiology / Natural History (6%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 94 | 67% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 7:15 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Arms and legs |
1 |
Limb undergrowth |
Lungs and breathing | 1 | Respiratory distress |
Laboratory research
19 |
13% |
Disease patterns and progression | 9 | 6% |
Patient case studies | 8 | 6% |
Other research | 4 | 3% |
Testing and diagnosis research | 4 | 3% |
Clinical study results | 3 | 2% |
Lee S (2026). [PMID: 41206258](https://pubmed.ncbi.nlm.nih.gov/41206258/). *Am J Geriatr Psychiatry*. [Review / Meta-Analysis]
Tsujioka Y (2026). [PMID: 42094029](https://pubmed.ncbi.nlm.nih.gov/42094029/). *Mol Syndromol*. [Review / Meta-Analysis]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Ferri C (2026). [PMID: 41798958](https://pubmed.ncbi.nlm.nih.gov/41798958/). *Front Immunol*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Buel KL (2026). [PMID: 41569909](https://pubmed.ncbi.nlm.nih.gov/41569909/). *FP Essent*. [Review / Meta-Analysis]
Mokos ZB (2025). [PMID: 40355033](https://pubmed.ncbi.nlm.nih.gov/40355033/). *Clin Dermatol*. [Review / Meta-Analysis]
Sakuma H (2025). [PMID: 39143740](https://pubmed.ncbi.nlm.nih.gov/39143740/). *Dev Med Child Neurol*. [Review / Meta-Analysis]
Pena C (2025). [PMID: 40146047](https://pubmed.ncbi.nlm.nih.gov/40146047/). *Minerva Med*. [Review / Meta-Analysis]